Skip to main content

Table 4 Incidence of adverse reactions

From: Short-term survival and safety of apatinib combined with oxaliplatin and S-1 in the conversion therapy of unresectable gastric cancer

Variable

Patients (N = 39)

 

Any grade, N (%)

Grade 3 or 4, N (%)

Leukopenia

27 (73.0)

0 (0)

Granulocytopenia

29 (78.4)

0 (0)

Thrombocytopenia

6 (16.2)

1 (2.7)

Elevated transaminase

9 (24.3)

0 (0)

Hand-foot syndrome

9 (24.3)

0 (0)

Stomatitis

14 (37.8)

0 (0)

Fatigue

20 (54.1)

0 (0)

Proteinuria

4 (10.8)

0 (0)

Gastrointestinal hemorrhage

2 (5.4)

1 (2.7)

Hypertension

10 (27.0)

1 (2.7)

Neurotoxicity

10 (27.0)

0 (0)

Gastrointestinal perforation

1 (2.7)

1 (2.7)